In prostate cancer, evaluation of the potential benefits of immunotherapy is done (143) Ipilimumab, an antibody which is anti-CTLA4, gives beneficial results in the clinical studies with patients having prostate cancer, no enhanced overall survival could be confirmed in subsequent bigger investigations, despite the fact that full remission was achieved in a few cases. Here, CTLA4 is linked to prostate cancer.